Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Aileron Therapeutics, Inc. (ALRN : NSDQ)
 
 • Company Description   
Aileron Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It engages in developing and commercializing a novel class of therapeutics primarily in the United States. The companys lead product includes ALRN-6924, targets the tumor suppressor protein p53 for the treatment of a range of cancers which are in clinical stage. Aileron Therapeutics, Inc. is based in Cambridge, Massachusetts.

Number of Employees: 9

 
 • Price / Volume Information   
Yesterday's Closing Price: $0.44 Daily Weekly Monthly
20 Day Moving Average: 315,965 shares
Shares Outstanding: 90.82 (millions)
Market Capitalization: $39.95 (millions)
Beta: 2.50
52 Week High: $1.40
52 Week Low: $0.32
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -18.02% -7.66%
12 Week 8.59% 19.39%
Year To Date -21.85% -4.51%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
285 Summer Street Suite 101
-
Boston,MA 02210
USA
ph: 617-995-0900
fax: -
rwanstall@aileronrx.com http://www.aileronrx.com
 
 • General Corporate Information   
Officers
Manuel C. Alves Aivado - President; Chief Executive Officer and Director
Jeffrey A. Bailey - Chairman of the Board of Directors
Richard J. Wanstall - Chief Financial Officer & Treasurer
Reinhard J. Ambros - Director
William T. McKee - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 00887A105
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/10/22
Share - Related Items
Shares Outstanding: 90.82
Most Recent Split Date: (:1)
Beta: 2.50
Market Capitalization: $39.95 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.09 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-0.38 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/10/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 1.11
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: -12.50%
vs. Previous Quarter: -12.50%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
03/31/22 - -59.30
12/31/21 - -49.47
09/30/21 - -54.04
ROA
03/31/22 - -54.13
12/31/21 - -45.81
09/30/21 - -49.50
Current Ratio
03/31/22 - 9.65
12/31/21 - 10.69
09/30/21 - 11.94
Quick Ratio
03/31/22 - 9.65
12/31/21 - 10.69
09/30/21 - 11.93
Operating Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Net Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Pre-Tax Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Book Value
03/31/22 - 0.40
12/31/21 - 0.48
09/30/21 - 0.55
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
Debt-to-Capital
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
 

Powered by Zacks Investment Research ©